Skip to main content
SpringerLink
Log in

Chronic Lymphocytic Leukemia (CLL)

  • Chapter
  • First Online:
Leukemia and Related Disorders

Part of the book series: Contemporary Hematology ((CH))

  • 1683 Accesses

Abstract

Chronic lymphocytic leukemia is the most common leukemia affecting adults in Western countries, accounting for about 30% of all leukemias. It is a clonal malignancy of mature CD5+ B-lymphocytes involving the peripheral blood, bone marrow, and lymphoid organs and has a distinct immunophenotype that allows differentiation from other B-cell lymphomas. Most patients with CLL present with a lymphocytosis at diagnosis; however, some patients present with lymphadenopathy alone. CLL is predominantly a disease of the elderly as the median age at diagnosis is 72 years. The clinical course of CLL is quite variable, with survival times from initial diagnosis ranging from 2 to 20 years.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Goldin LR, Caporaso NE. Family studies in chronic lymphocytic leukaemia and other lymphoproliferative tumours. Br J Haematol. 2007;139:774–9.

    PubMed  Google Scholar 

  2. Boelens J, Lust S, Vanhoecke B, Offner F. Chronic lymphocytic leukaemia. Anticancer Res. 2009;29:605–15.

    PubMed  CAS  Google Scholar 

  3. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.

    PubMed  Google Scholar 

  4. Linet MS, Schubauer-Berigan MK, Weisenburger DD, et al. Chronic lymphocytic leukaemia: an overview of aetiology in light of recent developments in classification and pathogenesis. Br J Haematol. 2007;139:672–86.

    PubMed  Google Scholar 

  5. Molica S, Levato D. What is changing in the natural history of chronic lymphocytic leukemia? Haematologica. 2001;86:8–12.

    PubMed  CAS  Google Scholar 

  6. Shanafelt TD, Byrd JC, Call TG, Zent CS, Kay NE. Narrative review: initial management of newly diagnosed, early-stage chronic lymphocytic leukemia. Ann Intern Med. 2006;145:435–47.

    PubMed  Google Scholar 

  7. Dores GM, Anderson WF, Curtis RE, et al. Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology. Br J Haematol. 2007;139:809–19.

    PubMed  Google Scholar 

  8. Finch SC, Hoshino T, Itoga T, Ichimaru M, Ingram Jr RH. Chronic lymphocytic leukemia in Hiroshima and Nagasaki, Japan. Blood. 1969;33:79–86.

    PubMed  CAS  Google Scholar 

  9. Gluzman D, Imamura N, Sklyarenko L, Nadgornaya V, Zavelevich M, Machilo V. Patterns of hematological malignancies in Chernobyl clean-up workers (1996–2005). Exp Oncol. 2006;28:60–3.

    PubMed  CAS  Google Scholar 

  10. Institute of Medicine of the National Academies. Veterans and agent orange. Washington, DC: National Academies Press; 2003. p. 242–392.

    Google Scholar 

  11. Yee KW, O’Brien SM. Chronic lymphocytic leukemia: diagnosis and treatment. Mayo Clin Proc. 2006;81:1105–29.

    PubMed  CAS  Google Scholar 

  12. Gomez SL, Quach T, Horn-Ross PL, et al. Hidden breast cancer disparities in Asian women: disaggregating incidence rates by ethnicity and migrant status. Am J Public Health. 2010;100 Suppl 1:S125–31.

    PubMed  Google Scholar 

  13. Mauro FR, Giammartini E, Gentile M, et al. Clinical features and outcome of familial chronic lymphocytic leukemia. Haematologica. 2006;91:1117–20.

    PubMed  Google Scholar 

  14. Yuille MR, Matutes E, Marossy A, Hilditch B, Catovsky D, Houlston RS. Familial chronic lymphocytic leukaemia: a survey and review of published studies. Br J Haematol. 2000;109:794–9.

    PubMed  CAS  Google Scholar 

  15. Goldin LR, Pfeiffer RM, Li X, Hemminki K. Familial risk of lymphoproliferative tumors in families of patients with chronic lymphocytic leukemia: results from the Swedish family-cancer database. Blood. 2004;104:1850–4.

    PubMed  CAS  Google Scholar 

  16. Slager SL, Kay NE. Familial chronic lymphocytic leukemia: what does it mean to me? Clin Lymphoma Myeloma. 2009;9 Suppl 3:S194–7.

    PubMed  Google Scholar 

  17. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005;352:804–15.

    PubMed  CAS  Google Scholar 

  18. Moreno C, Montserrat E. New prognostic markers in chronic lymphocytic leukemia. Blood Rev. 2008;22:211–9.

    PubMed  CAS  Google Scholar 

  19. Cheson BD, Bennett JM, Rai KR, et al. Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-Sponsored Working Group. Am J Hematol. 1988;29:152–63.

    PubMed  CAS  Google Scholar 

  20. Keating MJ, O’Brien S, Lerner S, et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood. 1998;92:1165–71.

    PubMed  CAS  Google Scholar 

  21. Robak E, Robak T. Skin lesions in chronic lymphocytic leukemia. Leuk Lymphoma. 2007;48:855–65.

    PubMed  Google Scholar 

  22. Wierda WG, Lamanna N, Weiss MA. Chronic lymphocytic leukemia. In: Cancer management: a multidisciplinary approach. 11th ed. Lawrence: CMPMedica; 2008. Chapter 34.

    Google Scholar 

  23. Dearden C. Disease-specific complications of chronic lymphocytic leukemia. Hematol Am Soc Hematol Educ Progr. 2008:450–6.

    Google Scholar 

  24. Diehl LF, Ketchum LH. Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia. Semin Oncol. 1998;25:80–97.

    PubMed  CAS  Google Scholar 

  25. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the international workshop on chronic lymphocytic leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446–56.

    PubMed  CAS  Google Scholar 

  26. Ghia P, Ferreri AM, Caligaris-Cappio F. Chronic lymphocytic leukemia. Crit Rev Oncol Hematol. 2007;64:234–46.

    PubMed  Google Scholar 

  27. Rawstron AC, Bennett FL, O’Connor SJ, et al. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med. 2008;359:575–83.

    PubMed  CAS  Google Scholar 

  28. Rossi D, Sozzi E, Puma A, et al. The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors. Br J Haematol. 2009;146:64–75.

    PubMed  Google Scholar 

  29. Rawstron AC, Hillmen P. Clinical and diagnostic implications of monoclonal B-cell lymphocytosis. Best Pract Res Clin Haematol. 2010;23:61–9.

    PubMed  CAS  Google Scholar 

  30. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46:219–34.

    PubMed  CAS  Google Scholar 

  31. Rai KR. A critical analysis of staging in CLL. In: Gale RP, Rai KR, editors. Chronic lymphocytic leukemia: recent progress and future directions. New York: Liss; 1987. p. 253–64.

    Google Scholar 

  32. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981;48:198–206.

    PubMed  CAS  Google Scholar 

  33. Wierda WG, O’Brien S, Wang X, et al. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood. 2007;109:4679–85.

    PubMed  CAS  Google Scholar 

  34. Bergmann MA, Eichhorst BF, Busch R, et al. Prospective evaluation of prognostic parameters in early stage chronic lymphocytic leukemia (CLL): results of the CLL1-protocol of the German CLL Study Group (GCLLSG). Blood (ASH Annu Meeting Abstr). 2007;110:625.

    Google Scholar 

  35. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910–6.

    PubMed  CAS  Google Scholar 

  36. Dal-Bo M, Bertoni F, Forconi F, et al. Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance. J Transl Med. 2009;7:76.

    PubMed  Google Scholar 

  37. Hamblin TJ. Prognostic markers in chronic lymphocytic leukaemia. Best Pract Res Clin Haematol. 2007;20:455–68.

    PubMed  CAS  Google Scholar 

  38. Kay NE, O’Brien SM, Pettitt AR, Stilgenbauer S. The role of prognostic factors in assessing ‘high-risk’ subgroups of patients with chronic lymphocytic leukemia. Leukemia. 2007;21:1885–91.

    PubMed  CAS  Google Scholar 

  39. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003;348:1764–75.

    PubMed  CAS  Google Scholar 

  40. CLL Trialists’ Collaborative Group. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. J Natl Cancer Inst. 1999;91:861–8.

    Google Scholar 

  41. Shanafelt TD, Rabe KG, Kay NE, et al. Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia. Cancer. 2010;116:4777–87.

    PubMed  Google Scholar 

  42. Shanafelt TD. Predicting clinical outcome in CLL: how and why. Hematol Am Soc Hematol Educ Progr. 2009:421–9.

    Google Scholar 

  43. Muntanola A, Bosch F, Arguis P, et al. Abdominal computed tomography predicts progression in patients with Rai stage 0 chronic lymphocytic leukemia. J Clin Oncol. 2007;25:1576–80.

    PubMed  Google Scholar 

  44. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000;343:1750–7.

    PubMed  CAS  Google Scholar 

  45. Johnson S, Smith AG, Loffler H, et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet. 1996;347:1432–8.

    PubMed  CAS  Google Scholar 

  46. Leporrier M, Chevret S, Cazin B, et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood. 2001;98:2319–25.

    PubMed  CAS  Google Scholar 

  47. Flinn IW, Neuberg DS, Grever MR, et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol. 2007;25:793–8.

    PubMed  CAS  Google Scholar 

  48. Eichhorst BF, Busch R, Hopfinger G, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood. 2006;107:885–91.

    PubMed  CAS  Google Scholar 

  49. Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 trial): a randomised controlled trial. Lancet. 2007;370:230–9.

    PubMed  CAS  Google Scholar 

  50. Weiss MA, Maslak PG, Jurcic JG, et al. Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia. J Clin Oncol. 2003;21:1278–84.

    PubMed  CAS  Google Scholar 

  51. Robak T, Blonski JZ, Wawrzyniak E, et al. Activity of cladribine combined with cyclophosphamide in frontline therapy for chronic lymphocytic leukemia with 17p13.1/TP53 deletion: report from the Polish Adult Leukemia Group. Cancer. 2009;115:94–100.

    PubMed  CAS  Google Scholar 

  52. Robak T, Blonski JZ, Gora-Tybor J, et al. Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). Blood. 2006;108:473–9.

    PubMed  CAS  Google Scholar 

  53. Bosch F, Ferrer A, Villamor N, et al. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication. Clin Cancer Res. 2008;14:155–61.

    PubMed  CAS  Google Scholar 

  54. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825–33.

    PubMed  CAS  Google Scholar 

  55. Manshouri T, Do KA, Wang X, et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood. 2003;101:2507–13.

    PubMed  CAS  Google Scholar 

  56. Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 2003;101:6–14.

    PubMed  CAS  Google Scholar 

  57. Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood. 2005;105:49–53.

    PubMed  CAS  Google Scholar 

  58. Tam CS, O’Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008;112:975–80.

    PubMed  CAS  Google Scholar 

  59. Hallek M, Fingerle-Rowson G, Fink A, et al. First-line treatment with fludarabine, cyclophosphamide, and rituximab improves overall survival in previously untreated patients with advanced chronic lymphocytic leukemia (CLL): results of a randomized phase III trial on behalf of an International Group of Investigators and the German CLL Study Group. Blood (ASH Annu Meeting Abstr). 2009;114:535.

    Google Scholar 

  60. Bosch F, Abrisqueta P, Villamor N, et al. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. J Clin Oncol. 2009;27:4578–84.

    PubMed  CAS  Google Scholar 

  61. Foon KA, Boyiadzis M, Land SR, et al. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2009;27:498–503.

    PubMed  CAS  Google Scholar 

  62. Lamanna N, Jurcic JG, Noy A, et al. Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses. J Clin Oncol. 2009;27:491–7.

    PubMed  CAS  Google Scholar 

  63. Kay NE, Geyer SM, Call TG, et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood. 2007;109:405–11.

    PubMed  CAS  Google Scholar 

  64. Shanafelt TD, Lin T, Geyer SM, et al. Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. Cancer. 2007;109:2291–8.

    PubMed  CAS  Google Scholar 

  65. Reynolds C, Di Bella N, Lyons RM, et al. Phase III trial of fludarabine, cyclophosphamide, and rituximab vs pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia. Blood (ASH Annu Meeting Abstr). 2008;112:327.

    Google Scholar 

  66. Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol. 2007;25:5616–23.

    PubMed  CAS  Google Scholar 

  67. Parikh SA, Keating M, O’Brien S, et al. Frontline combined chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab and rituximab in high-risk chronic lymphocytic leukemia. Blood (ASH Annu Meeting Abstr). 2009;114:208.

    Google Scholar 

  68. Zent CS, Call TG, Shanafelt DT, et al. Alemtuzumab and rituximab for initial treatment of high risk, early stage chronic lymphocytic leukemia. Blood (ASH Annu Meeting Abstr). 2007;110:2050.

    Google Scholar 

  69. Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2009;27:4378–84.

    PubMed  CAS  Google Scholar 

  70. Fischer K, Cramer P, Stilgenbauer S, et al. Bendamustine combined with rituximab in first-line therapy of advanced CLL: a multicenter phase II trial of the German CLL Study Group (GCLLSG). Blood (ASH Annu Meeting Abstr). 2009;114:205.

    Google Scholar 

  71. Cheson BD, Rummel MJ. Bendamustine: rebirth of an old drug. J Clin Oncol. 2009;27:1492–501.

    PubMed  CAS  Google Scholar 

  72. Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2010;28:1749–55.

    PubMed  CAS  Google Scholar 

  73. Wierda WG, Kipps TJ, Dürig J, et al. Ofatumumab combined with fludarabine and cyclophosphamide shows high activity in patients with previously untreated chronic lymphocytic leukemia: results from a randomized, multicenter, international, two-dose, parallel group, phase II trial. Blood (ASH Annu Meeting Abstr). 2009;114:207.

    Google Scholar 

  74. Schweighofer CD, Ritgen M, Eichhorst BF, et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). Br J Haematol. 2009;144:95–8.

    PubMed  CAS  Google Scholar 

  75. Del Poeta G, Del Principe MI, Buccisano F, et al. Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. Cancer. 2008;112:119–28.

    PubMed  Google Scholar 

  76. Wierda W, O’Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol. 2005;23:4070–8.

    PubMed  CAS  Google Scholar 

  77. Bosch F, Ferrer A, Lopez-Guillermo A, et al. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br J Haematol. 2002;119:976–84.

    PubMed  CAS  Google Scholar 

  78. Lamanna N, Kalaycio M, Maslak P, et al. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol. 2006;24:1575–81.

    PubMed  CAS  Google Scholar 

  79. Elter T, Borchmann P, Schulz H, et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol. 2005;23:7024–31.

    PubMed  CAS  Google Scholar 

  80. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002;99:3554–61.

    PubMed  CAS  Google Scholar 

  81. Stilgenbauer S, Zenz T, Winkler D, et al. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2009;27:3994–4001.

    PubMed  CAS  Google Scholar 

  82. Moreton P, Kennedy B, Lucas G, et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol. 2005;23:2971–9.

    PubMed  CAS  Google Scholar 

  83. Badoux XC, Keating M, O’Brien S, et al. Chemoimmunotherapy with cyclophosphamide, fludarabine, alemtuzumab and rituximab is effective in relapsed patients with chronic lymphocytic leukemia. Blood (ASH Annu Meeting Abstr). 2009;114:3431.

    Google Scholar 

  84. Lin TS, Donohue KA, Byrd JC, et al. Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy improves the complete response rate in chronic lymphocytic leukemia and eradicates minimal residual disease but is associated with severe infectious toxicity: final analysis of CALGB study 10101. Blood (ASH Annu Meeting Abstr). 2009;114:210.

    Google Scholar 

  85. Tsimberidou AM, Wierda WG, Plunkett W, et al. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter’s syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2008;26:196–203.

    PubMed  CAS  Google Scholar 

  86. Mauro FR, Foa R, Meloni G, et al. Fludarabine, ara-C, novantrone and dexamethasone (FAND) in previously treated chronic lymphocytic leukemia patients. Haematologica. 2002;87:926–33.

    PubMed  CAS  Google Scholar 

  87. Engert A, Gercheva L, Robak T, et al. Improved progression-free survival of alemtuzumab plus fludarabine versus fludarabine alone as second-line treatment of patients with B-cell chronic lymphocytic leukemia: preliminary results from a phase III randomized trial. Blood (ASH Annu Meeting Abstr). 2009;114:537.

    Google Scholar 

  88. Faderl S, Ferrajoli A, Wierda W, O’Brien S, Lerner S, Keating MJ. Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence. Cancer. 2010;116:2360–5.

    PubMed  CAS  Google Scholar 

  89. Castro JE, Sandoval-Sus JD, Bole J, Rassenti L, Kipps TJ. Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia. 2008;22:2048–53.

    PubMed  CAS  Google Scholar 

  90. Bowen DA, Call TG, Jenkins GD, et al. Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leuk Lymphoma. 2007;48:2412–7.

    PubMed  CAS  Google Scholar 

  91. Dungarwalla M, Evans SO, Riley U, Catovsky D, Dearden CE, Matutes E. High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy. Haematologica. 2008;93:475–6.

    PubMed  Google Scholar 

  92. Weide R, Pandorf A, Heymanns J, Koppler H. Bendamustine/mitoxantrone/rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study. Leuk Lymphoma. 2004;45:2445–9.

    PubMed  CAS  Google Scholar 

  93. Khouri IF, Keating MJ, Vriesendorp HM, et al. Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results. J Clin Oncol. 1994;12:748–58.

    PubMed  CAS  Google Scholar 

  94. Pavletic ZS, Bishop MR, Bierman PJ, Armitage JO. Bone marrow transplantation in chronic lymphocytic leukemia and lymphomas. Biomed Pharmacother. 1996;50:118–24.

    PubMed  CAS  Google Scholar 

  95. Milligan DW, Fernandes S, Dasgupta R, et al. Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses. Blood. 2005;105:397–404.

    PubMed  CAS  Google Scholar 

  96. Gribben JG, Zahrieh D, Stephans K, et al. Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood. 2005;106:4389–96.

    PubMed  CAS  Google Scholar 

  97. Ritgen M, Lange A, Stilgenbauer S, et al. Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia. Blood. 2003;101:2049–53.

    PubMed  CAS  Google Scholar 

  98. Dreger P, Stilgenbauer S, Benner A, et al. The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status. Blood. 2004;103:2850–8.

    PubMed  CAS  Google Scholar 

  99. Jantunen E, Itala M, Siitonen T, et al. Autologous stem cell transplantation in patients with chronic lymphocytic leukaemia: the Finnish experience. Bone Marrow Transplant. 2006;37:1093–8.

    PubMed  CAS  Google Scholar 

  100. Michallet M, Archimbaud E, Bandini G, et al. HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. European Group for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry. Ann Intern Med. 1996;124:311–5.

    PubMed  CAS  Google Scholar 

  101. Khouri IF, Lee MS, Saliba RM, et al. Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Exp Hematol. 2004;32:28–35.

    PubMed  CAS  Google Scholar 

  102. Khouri IF, Saliba RM, Admirand J, et al. Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia. Br J Haematol. 2007;137:355–63.

    PubMed  CAS  Google Scholar 

  103. Brown JR, Kim HT, Li S, et al. Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. Biol Blood Marrow Transplant. 2006;12:1056–64.

    PubMed  Google Scholar 

  104. Schetelig J, Thiede C, Bornhauser M, et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol. 2003;21:2747–53.

    PubMed  CAS  Google Scholar 

  105. Delgado J, Thomson K, Russell N, et al. Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study. Blood. 2006;107:1724–30.

    PubMed  CAS  Google Scholar 

  106. Sorror ML, Storer BE, Sandmaier BM, et al. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol. 2008;26:4912–20.

    PubMed  Google Scholar 

  107. Byrd JC, Kipps TJ, Flinn IW, et al. Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Blood. 2010;115:489–95.

    PubMed  CAS  Google Scholar 

  108. Furman RR, Forero-Torres A, Shustov A, Drachman JG. A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2010;51:228–35.

    PubMed  CAS  Google Scholar 

  109. Luqman M, Klabunde S, Lin K, et al. The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells. Blood. 2008;112:711–20.

    PubMed  CAS  Google Scholar 

  110. Lin TS, Ruppert AS, Johnson AJ, et al. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol. 2009;27:6012–8.

    PubMed  CAS  Google Scholar 

  111. Chanan-Khan A, Miller KC, Musial L, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol. 2006;24:5343–9.

    PubMed  CAS  Google Scholar 

  112. Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood. 2008;111:5291–7.

    PubMed  CAS  Google Scholar 

  113. Ferrajoli A, Badoux XC, O’Brien S, et al. Combination therapy with lenalidomide and rituximab in patients with relapsed chronic lymphocytic leukemia. Blood (ASH Annu Meeting Abstr). 2009;114:206.

    Google Scholar 

  114. O’Brien S, Moore J, Ding L, Novick S, Rai K. Addition of oblimersen (Bcl-2 antisense) to fludarabine cyclophosphamide for relapsed/refractory chronic lymphocytic leukemia extends survival in patients who achieve CR/nPR: results from a randomized phase 3 study. Blood (ASH Annu Meeting Abstr). 2007;110:751.

    Google Scholar 

  115. Herman SE, Gordon AL, Wagner AJ, et al. The phosphatidylinositol 3-kinase-{delta} inhibitor CAL-101 demonstrates promising pre-clinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood. 2010;116(12):2078–88.

    PubMed  CAS  Google Scholar 

  116. Pinilla-Ibarz J, McQuary A. Chronic lymphocytic leukemia: putting new treatment options into perspective. Cancer Control. 2010;17:4–15; quiz 16.

    PubMed  Google Scholar 

  117. Balakrishnan K, Verma D, O’Brien S, et al. Phase II and pharmacodynamic study of oral forodesine in patients with advanced and/or fludarabine-treated chronic lymphocytic leukemia. Blood. 2010;116(6):886–92.

    PubMed  CAS  Google Scholar 

  118. Gandhi V, Plunkett W, Bonate PL, et al. Clinical and pharmacokinetic study of clofarabine in chronic lymphocytic leukemia: strategy for treatment. Clin Cancer Res. 2006;12:4011–7.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, University of Colorado School of Medicine, 1665 Aurora Court, Room 2251A, Aurora, CO, 80045, USA

    Jonathan A. Gutman M.D.

  2. Divisions of Hematology and Oncology, University of Washington School of Medicine, Seattle, WA, USA

    Kelly M. Smith M.D.

  3. Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA

    John M. Pagel M.D., Ph.D. (Associate Professor)

  4. Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D5-380, Seattle, WA, 98109, USA

    John M. Pagel M.D., Ph.D. (Associate Member)

Authors
  1. Jonathan A. Gutman M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kelly M. Smith M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John M. Pagel M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. John M. Pagel M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John M. Pagel M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. Univ of Washington School of Medicine, Member,, Professor of Med, Division of Hematology, Attending Physician, Seattle Cancer Care Alliance, Seattle, 98109-1024, Washington, USA

    Elihu H. Estey

  2. Director, Clinical Research Division,, Fred Hutchinson Cancer Research Center, Professor of Medicine; Head of Oncology, Seattle Cancer Care Alliance, Univ of Washington Sch of Med, Seattle, 98109-1024, Washington, USA

    Fred R. Appelbaum

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Gutman, J.A., Smith, K.M., Pagel, J.M., Pagel, J.M. (2012). Chronic Lymphocytic Leukemia (CLL). In: Estey, E., Appelbaum, F. (eds) Leukemia and Related Disorders. Contemporary Hematology. Springer, New York, NY. https://doi.org/10.1007/978-1-60761-565-1_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-565-1_3

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-60761-564-4

  • Online ISBN: 978-1-60761-565-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation